» Articles » PMID: 33806241

Strategies to Potentiate Paracrine Therapeutic Efficacy of Mesenchymal Stem Cells in Inflammatory Diseases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Apr 3
PMID 33806241
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) have been developed as cell therapeutics for various immune disorders using their immunoregulatory properties mainly exerted by their paracrine functions. However, variation among cells from different donors, as well as rapid clearance after transplantation have impaired the uniform efficacy of MSCs and limited their application. Recently, several strategies to overcome this limitation have been suggested and proven in pre-clinical settings. Therefore, in this review article, we will update the knowledge on bioengineering strategies to improve the immunomodulatory functions of MSCs, including genetic modification and physical engineering.

Citing Articles

Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment.

Kangari P, Salahlou R, Vandghanooni S Adv Pharm Bull. 2024; 14(3):574-590.

PMID: 39494266 PMC: 11530882. DOI: 10.34172/apb.2024.052.


Autologous Fat Grafting-A Panacea for Scar Tissue Therapy?.

Ahmad N, Anker A, Klein S, Dean J, Knoedler L, Remy K Cells. 2024; 13(16).

PMID: 39195271 PMC: 11352477. DOI: 10.3390/cells13161384.


Immunomodulatory performance of GMP-compliant, clinical-grade mesenchymal stromal cells from four different sources.

Kazem Arki M, Moeinabadi-Bidgoli K, Niknam B, Mohammadi P, Hassan M, Hossein-Khannazer N Heliyon. 2024; 10(2):e24948.

PMID: 38312681 PMC: 10835001. DOI: 10.1016/j.heliyon.2024.e24948.


Integrin beta 3-overexpressing mesenchymal stromal cells display enhanced homing and can reduce atherosclerotic plaque.

Hu H, Xiao X, Li T, Liu D, Geng X, Han M World J Stem Cells. 2023; 15(9):931-946.

PMID: 37900938 PMC: 10600744. DOI: 10.4252/wjsc.v15.i9.931.


Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges.

Tian C, Zhang Y, Yang M, Xu H, Zhu M, Yao J J Inflamm Res. 2023; 16:2089-2119.

PMID: 37215379 PMC: 10199681. DOI: 10.2147/JIR.S400447.


References
1.
Negi N, Griffin M . Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. Stem Cells. 2020; 38(5):596-605. PMC: 7217190. DOI: 10.1002/stem.3151. View

2.
Luz-Crawford P, Kurte M, Bravo-Alegria J, Contreras R, Nova-Lamperti E, Tejedor G . Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 2013; 4(3):65. PMC: 3706898. DOI: 10.1186/scrt216. View

3.
Zheng G, Qiu G, Ge M, He J, Huang L, Chen P . Human adipose-derived mesenchymal stem cells alleviate obliterative bronchiolitis in a murine model via IDO. Respir Res. 2017; 18(1):119. PMC: 5472885. DOI: 10.1186/s12931-017-0599-5. View

4.
Garcia J, Quiros M, Han W, OLeary M, Cox G, Nusrat A . IFN-γ-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. Biomaterials. 2019; 220:119403. PMC: 6717550. DOI: 10.1016/j.biomaterials.2019.119403. View

5.
Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View